Pharma business news, market intelligence, and CEO-level case studies.

Novo Nordisk vs Eli Lilly: The Obesity Ad War Neither Side Can Win on Evidence | Witfire Elite Witfire Elite · Litigation Risk Brief · GLP-1 Series No.… ...

Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...

Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...

Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...

FDA gave Sobi a Complete Response Letter for NASP in uncontrolled gout, but the letter did not attack the clinical case. It attacked manufacturing control, CMC readiness and contract manufacturing ...

Bright biotech illustration for Unicycive’s OLC CRL, showing nanoparticle formulation, manufacturing control strategy, FDA quality risk and CDMO execution failure. The FDA did not reject Oxylanthanum ...

Viridian’s Lumvoa approval is not only a new thyroid eye disease launch. It is the first real crack in Amgen’s Tepezza-controlled market. The label is broad, the course is shorter, and the diplopia ...

AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved something else: early clinical safety, brain exposure, and a novel CNS mechanism can still be valuable enough to move a small ...

A bright clinical concept image showing the stabilizer ceiling in amyloidosis, where modern background therapy reduces the detectable benefit of add-on drugs. HELIOS-B cleared its endpoint.

4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence moat before Bristol Myers Squibb brings a ...

GSK did not simply acquire Nuvalent. It bought two FDA decision dates, a shortcut back into lung cancer, and a pre-approval stake in rebuilding its oncology identity before the market could fully ...